Q-omics provides the consensus-scored EFR3B profile across patient tissues and cancer cell-line models. EFR3B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, EFR3B is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, EFR3B RNA expression shows 18,701 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight PAAD, LUAD, and THYM as cancer lineages where EFR3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EFR3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EFR3B survival associations across molecular data types. EFR3B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EFR3B RNA expression–survival associations across cancer types. High EFR3B expression shows unfavorable associations in LIHC, KIRP, ACC and MESO, but favorable associations in PAAD and LGG. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for EFR3B RNA expression.
This table summarizes EFR3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for EFR3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EFR3B shows lower tumor expression in LUAD, LUSC and KIRC and higher tumor expression in BRCA, LIHC and UCEC. The LUAD box plot shows higher EFR3B RNA expression in normal versus tumor tissue (log2 FC = −1.342, t-test p < 0.001).
This table shows molecular features associated with EFR3B in patient tissues and cancer cell lines. In patient samples, EFR3B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, EFR3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
